Conclusion: Our study shows that CKD4/6 inhibition increases oxidative metabolism and improves mitochondrial function. These effects may be mediating some of the protective effects of palbociclib in ...
Currently, abemaciclib, palbociclib, and ribociclib are the approved CKD4/6 inhibitors. While these are well tolerated, they have side effects, including anemia. Therefore, it is difficult to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback